Double‐blind trial of recombinant γ‐interferon versus placebo in the treatment of rheumatoid arthritis

Abstract

One hundred five patients were enrolled in a 12‐week, randomized, prospective, double‐blind, placebo‐controlled trial of recombinant human γ‐interferon (rHuγ‐IFN) for the treatment of rheumatoid arthritis. Fifty‐four patients received rHuγ‐IFN and 51 received placebo. Forty‐two patients in each group completed the 12‐week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHuγ‐IFN was greater than that with placebo, the differences were generally not statistically significant.